JAKARTA, Indonesia, March 20, 2023 /PRNewswire/ PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. This round of financing will be used for further strengthening the company's pipeline and portfolio especially in Oncology area to be drug substances manufacturing facilities. Etana is committed to build production capacity for mammalian cell for monoclonal antibodies drug substance to ensure high local content production and technology capability. Currently, Etana focuses on local biopharmaceutical production for mRNA platforms, proteins and monoclonal antibodies. The Inauguration of Etana factory by the President of the Republic Indonesia, Joko Widodo accompanied by by Coordinating Minister for Maritime Affairs and Investment, Luhut Binsar Pandjaitan (right) and President Director of Etana, Nathan Tirtana (left) "Etana as an Indo
Total deals worth $755.9m were announced in Asia-Pacific's medical devices industry deal activity during June 2022 compared to last 12 months: GlobalData
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies.
[maximum single financing! Is "flying car" a tuyere or Bubble? On October 19th, Xiaopeng Automobile Ecological Enterprise Xiaopeng Huitian announced that it had completed round A financing of more than US $500m, with a pre-investment valuation of more than US $1 billion. It is reported that this round of financing is led by IDG Capital, Wuyuan Capital and Xiaopeng Automobile, followed by Sequoia Capital China, Zhong Ding Capital, GGV GGV Capital, Hillhouse Venture Capital, Yunfeng Fund and other well-known institutions.